eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.

eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs). Translation is the process in cells whereby the synthesis of proteins is directed by information contained in genetic sequences.  Each of eFFECTOR’s product candidates is designed to act on a single protein that regulates, in a coordinated manner, the expression of multiple functionally related proteins that together drive important biological processes such as immune evasion, stress and inflammatory responses, as well as cell proliferation.

Abingworth

Alexandria Venture Investments

Altitude Life Science Ventures

SR One

The Column Group

U.S. Venture Partners

OUP (Osage University Partners)

Pfizer Venture Investments

BioMed Ventures

Sectoral Asset Management

Astellas Venture Management

Novartis Venture Fund

Mission BioCapital

#Cancer is complex – but one thing remains simple: Our gratitude. From all of us at eFFECTOR, thank you to all those who continue to support our goal to overcome cancer's complexities. Without you, we wouldn't be able to continue to deliver on our promise to advance our clinical pipeline for patients.


We look forward to presenting new data at the San Antonio Breast Cancer Symposium this December 5-9. If you’re eager to learn more about our data, read the press release, here: https://brnw.ch/21wEt1A #SABCS23

At this year’s RNA Processing in Cancer Conference in Houston, Texas, our CEO Steve Worland will be speaking on “translation control in cancer.” Catch the panel on November 14! To view the whole agenda, see here #RNACancerSRC: https://brnw.ch/21wEkTH


Want to learn more about our small-molecule selective translation regulator inhibitors (STRIs)? Read this Genetic Engineering & Biotechnology News article by Gail Dutton to understand how we are targeting the eukaryotic initiation factor 4F (eIF4F) complex to attack and fight #cancer: https://brnw.ch/21wEdQE

Our management team will present at the Stifel Financial Corp. Healthcare Conference in New York from November 14-15. We look forward to connecting! Click for more details: https://brnw.ch/21wEbZL


COM:EFFECTOR